CA2840997A1 - Vaccine composition for transdermal administration - Google Patents

Vaccine composition for transdermal administration Download PDF

Info

Publication number
CA2840997A1
CA2840997A1 CA2840997A CA2840997A CA2840997A1 CA 2840997 A1 CA2840997 A1 CA 2840997A1 CA 2840997 A CA2840997 A CA 2840997A CA 2840997 A CA2840997 A CA 2840997A CA 2840997 A1 CA2840997 A1 CA 2840997A1
Authority
CA
Canada
Prior art keywords
receptor agonist
receptor
receptor antagonist
agonist
neu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2840997A
Other languages
English (en)
French (fr)
Inventor
Katsuyuki Okubo
Yoshiki Maeda
Takuya Shishido
Daisuke Asari
Arimichi Okazaki
Kyohei Matsushita
Wenjing Li
Mitsuhiko Hori
Haruo Sugiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of CA2840997A1 publication Critical patent/CA2840997A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2840997A 2013-02-05 2014-01-29 Vaccine composition for transdermal administration Abandoned CA2840997A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013020799 2013-02-05
JP2013-020799 2013-02-05

Publications (1)

Publication Number Publication Date
CA2840997A1 true CA2840997A1 (en) 2014-08-05

Family

ID=50028736

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2840997A Abandoned CA2840997A1 (en) 2013-02-05 2014-01-29 Vaccine composition for transdermal administration

Country Status (8)

Country Link
US (1) US20140220100A1 (enExample)
EP (1) EP2762158A1 (enExample)
JP (1) JP2014169278A (enExample)
KR (1) KR20140100415A (enExample)
CN (1) CN103961696A (enExample)
CA (1) CA2840997A1 (enExample)
IN (1) IN2014CH00390A (enExample)
RU (1) RU2014102938A (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841014A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Tape preparation of wt1 peptide cancer vaccine for transdermal administration
CN103961307B (zh) 2013-02-05 2019-11-29 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
TW201618790A (zh) * 2014-10-02 2016-06-01 Nitto Denko Corp 經皮投與用疫苗醫藥組合物
US20230233480A1 (en) * 2019-10-24 2023-07-27 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of fingolimod

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
EP1377299A4 (en) * 2001-03-19 2009-11-11 Intercell Usa Inc TRANSCUTANE IMMUNOSTIMULATION
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
WO2005089777A1 (en) 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
DE102004049223A1 (de) 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
WO2008011672A1 (en) * 2006-07-25 2008-01-31 4G Vaccines Pty Ltd A cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide
US20080112974A1 (en) 2006-09-08 2008-05-15 Duotol Ab Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens
EP2162149B1 (en) * 2007-06-01 2013-11-06 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Vaccine for the prevention of breast cancer relapse
US9764012B2 (en) * 2009-04-01 2017-09-19 University Of Miami Vaccine compositions and methods of use thereof
CN102475886A (zh) * 2010-11-29 2012-05-30 南开大学 新型抗乳腺癌多肽疫苗

Also Published As

Publication number Publication date
CN103961696A (zh) 2014-08-06
EP2762158A1 (en) 2014-08-06
KR20140100415A (ko) 2014-08-14
US20140220100A1 (en) 2014-08-07
JP2014169278A (ja) 2014-09-18
IN2014CH00390A (enExample) 2015-07-31
RU2014102938A (ru) 2015-08-10

Similar Documents

Publication Publication Date Title
US10071051B2 (en) WT1 peptide cancer vaccine composition for transdermal administration
EP2762155B1 (en) Vaccine Composition
US10449144B2 (en) WT1 peptide cancer vaccine composition for transdermal administration
US10195258B2 (en) Tape preparation of WT1 peptide cancer vaccine for transdermal administration
CA2840954A1 (en) Vaccine composition for transdermal or mucosal administration
JP2009510133A (ja) がん治療のためのビヒクルとして連続的疎水性相を含む担体におけるリポソームの使用
EP2762158A1 (en) E75-vaccine composition for transdermal administration
EP3189851A1 (en) Vaccine pharmaceutical composition for suppressing apoptosis of ctl or inhibiting suppression of induction of ctl

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190129